Latest Breaking News On - Docmorris adipositas care - Page 1 : comparemela.com

Zur Rose Group signals dynamic revenue development in the first quarter of 2021 EQS Group-News: Zur Rose Group AG / Key word(s): Quarterly / Interim Statement 20.04.2021 / 07:00 - - Strong sales growth in Germany of 25.2 per cent - Expansion of the DocMorris healthcare platform with new services - Continuation of integration activities: Merger of apo-rot with DocMorris The Zur Rose Group posted significant sales growth of 16.0 per cent in local currency terms in the first quarter of 2021, continuing along the growth path, even compared to the exceptionally strong previous year s quarter. In Group currency terms, revenue increased 17.8 per cent to CHF 502.7 million [1] despite the decline in demand for flu and cold medication resulting from the tightened hygiene measures. The general move towards more online purchases and the continued positive trend in new clients contributed to the dynamic development. The number of active customers rose by more

Christoph herrmannZur roseGermany the zur rose groupHead of group communicationsZur rose groupSwiss zur rose group is europeSwiss exchangeZur rose group ag keyNovo nordiskInterim statementRose groupDocmorris adipositasDocmorris adipositas careCapital markets daySwiss zur rose groupகிறிஸ்டோஃப் ஹெர்மன்